Explorative Cost-Effectiveness Analysis of a Rapid ID/AST Solution for Patients with Bloodstream Infection
Author(s)
Boughazi HE1, Textoris J2, Vandepitte S3
1bioMérieux, Marcy-L'étoile, Rhône, France, 2bioMérieux, Marcy L'étoile, Rhône, France, 3BioMérieux, Brussels, Belgium
Presentation Documents
OBJECTIVES: To explore the cost-effectiveness of a rapid ID/AST solutions in the management of patients with bloodstream infection compared to standard of care from a French payer perspective.
METHODS: A decision-analytic model based on the published literature and clinical expert validation was build comparing both health outcomes and direct healthcare costs of a hypothetical BSI in-hospital patient cohort diagnosed with and without a rapid ID/AST solution (i.e., results within 6h). A short-term time horizon until discharge or death was applied and the incremental cost-effectiveness ratio was calculated to estimate the cost per death averted. To deal with uncertainty and to test robustness of the model, one-way and probabilistic sensitivity analyses were conducted.
RESULTS: The use of a rapid ID/AST solution was cost-saving and lifesaving when compared to standard of care in BSI management, by starting earlier with appropriate treatment. In terms of clinical outcomes, rapid ID/AST reduced mortality by 3.8%, sepsis cases by 8.9% and septic shock cases by 4.6% (base case analysis). In terms of economic outcomes, a rapid ID/AST solution generated cost-savings of 794€ per BSI patient and a reduction of 1.5 general ward bed-days/patient while reducing ICU-stay with 1.1 day/patient. The sensitivity analyses demonstrated robustness of the base-case results.
CONCLUSIONS: Our model indicates that the introduction of a rapid ID/AST solution to manage in-hospital patients with BSI is a dominant/cost-saving strategy compared to SoC by reducing time to appropriate treatment. As a result, when clinicians will act upon these results in a real clinical setting, overall inappropriate empiric antibiotic prescriptions will be reduced which is then expected to decrease deterioration into sepsis and may have a positive impact on the burden of antimicrobial resistance on the long-term. Finally, the results of this explorative model, demonstrating both high medical and economic value, are in line with the WHO AMR priority recommendations.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
EE639
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Infectious Disease (non-vaccine), Medical Devices, No Additional Disease & Conditions/Specialized Treatment Areas